Zacks Investment Research upgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a buy rating in a research note issued to investors on Monday morning. Zacks Investment Research currently has $19.00 price target on the medical instruments supplier’s stock.

According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”

Other equities research analysts have also recently issued reports about the company. TheStreet cut AngioDynamics from a b- rating to a c rating in a research note on Tuesday, January 2nd. Canaccord Genuity restated a hold rating and issued a $17.00 price target on shares of AngioDynamics in a research report on Sunday, October 8th. KeyCorp restated a hold rating on shares of AngioDynamics in a research report on Friday, September 29th. Craig Hallum lowered AngioDynamics from a buy rating to a hold rating in a research report on Friday, January 5th. Finally, BidaskClub lowered AngioDynamics from a hold rating to a sell rating in a research report on Saturday, January 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $18.60.

Shares of AngioDynamics (ANGO) opened at $16.52 on Monday. The company has a market capitalization of $602.63, a price-to-earnings ratio of -78.66, a PEG ratio of 1.58 and a beta of 1.04. AngioDynamics has a 52 week low of $14.80 and a 52 week high of $18.85. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.56 and a quick ratio of 1.65.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The company had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the firm earned $0.19 EPS. sell-side analysts predict that AngioDynamics will post 0.69 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of ANGO. SG Americas Securities LLC bought a new position in shares of AngioDynamics in the 3rd quarter worth $143,000. Trexquant Investment LP bought a new position in shares of AngioDynamics in the 3rd quarter worth $175,000. Teachers Retirement System of The State of Kentucky boosted its position in shares of AngioDynamics by 54.9% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 3,900 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of AngioDynamics by 74.7% in the 2nd quarter. GSA Capital Partners LLP now owns 18,706 shares of the medical instruments supplier’s stock worth $303,000 after purchasing an additional 7,999 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new position in shares of AngioDynamics in the 2nd quarter worth $311,000. Institutional investors and hedge funds own 94.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/angiodynamics-ango-raised-to-buy-at-zacks-investment-research/1823170.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.